IL13
IL13 is a key Th2 cytokine that acts as a master driver of the allergic response and mucosal defense. It is a central mediator of airway hyper-reactivity, mucus secretion, and tissue remodeling in asthma.
Key Takeaways
- •IL13 is the primary cytokine responsible for the "symptoms" of asthma: mucus and airway twitchiness.
- •It drives the class-switching of B cells to produce IgE, the main antibody of allergy.
- •The R130Q variant (rs20541) makes the cytokine "stickier" to its receptor, increasing asthma risk.
- •Novel biologics like Dupilumab work by blocking the shared receptor for both IL-4 and IL-13.
Basic Information
- Gene Symbol
- IL13
- Full Name
- Interleukin 13
- Also Known As
- IL-13ALRHP600
- Location
- 5q31.1
- Protein Type
- Cytokine / Inflammatory Mediator
- Protein Family
- Interleukin-13 family
Related Isoforms
Key SNPs
The most significant IL13 variant; leads to increased protein stability and higher circulating levels, strongly linked to asthma and atopy.
Associated with increased IL13 transcription and elevated IgE levels in allergic individuals.
A marker used in GWAS to identify the 5q31 "cytokine cluster" associated with inflammatory and respiratory health.
Overview
Interleukin 13 (IL13) is a cytokine secreted primarily by T-helper type 2 (Th2) cells and type 2 innate lymphoid cells (ILC2s). It is a central player in the "Type 2" immune response, which evolved to defend the body against parasitic worms (helminths) but is also the driving force behind modern allergic diseases.
While IL13 shares many functions with IL-4, it has a unique and potent effect on non-immune cells. In the lungs, IL13 acts directly on airway smooth muscle and epithelial cells, inducing the production of thick mucus and making the airways hypersensitive to environmental triggers. Because of this, IL13 is considered the definitive "effector" cytokine of the asthmatic airway.
Conceptual Model
A simplified mental model for the pathway:
IL13 is the body's attempt to "wash and push" parasites out of the system.
Core Health Impacts
- • Mucus Secretion: Induces goblet cell hyperplasia and the production of MUC5AC mucus
- • Airway Twitchiness: Directly increases the contractility of airway smooth muscle cells
- • IgE Production: Promotes B-cell class switching to IgE, fueling the allergic cascade
- • Tissue Fibrosis: Stimulates fibroblasts to produce collagen and upregulate TGF-beta
- • Parasite Defense: Essential for the "weep and sweep" response needed to clear intestinal worms
Protein Domains
Four-Helix Bundle
The characteristic structural fold of the short-chain cytokine family, optimized for receptor interaction.
Receptor Binding Site
A dual-interface site that allows IL13 to bind first to IL-13Ra1 and then recruit the IL-4Ra subunit.
Upstream Regulators
Th2 Cells Activator
The primary source of IL13 in the adaptive immune response to allergens and parasites.
ILC2s Activator
Innate lymphoid cells that produce massive amounts of IL13 in response to epithelial "alarmins."
IL-4 Activator
Synergizes with IL13 and promotes the differentiation of the Th2 cells that produce it.
IL-33 / TSLP Activator
Epithelial-derived cytokines that act as "master switches" to turn on IL13 production during injury.
Allergens Activator
Environmental triggers (pollen, dust mites) that initiate the immune cascade leading to IL13 release.
Downstream Targets
IL-13 Receptor (IL-13Rα1) Activates
The primary signaling receptor; forms a complex with IL-4Rα to initiate the STAT6 cascade.
IL-13 Receptor (IL-13Rα2) Activates
A high-affinity "decoy" receptor that binds IL13 but does not signal, acting as a natural brake.
STAT6 Activates
The master transcription factor for IL13 signaling; moves to the nucleus to turn on allergy genes.
Mucus Proteins (MUC5AC) Activates
The primary structural protein of airway mucus, upregulated directly by IL13.
IgE Antibodies Activates
IL13 signaling in B-cells is a requirement for the production of allergen-specific IgE.
TGF-β1 Activates
IL13 triggers the production of this master fibrotic regulator, linking inflammation to scarring.
Role in Aging
IL13 plays a dual role in aging, primarily focused on the lungs and the gut. While it is essential for barrier maintenance, its chronic elevation in older adults contributes to the "Type 2 Inflammaging" that drives tissue stiffening and reduced organ resilience.
Airway Remodeling
Decades of IL13-driven inflammation lead to permanent thickening of the airway walls, a form of respiratory aging known as fixed obstruction.
Fibrotic Progression
IL13 is a potent driver of age-related fibrosis in the liver and lungs, acting as a bridge between chronic inflammation and permanent scarring.
Mucosal Barrier Decay
Dysregulated IL13 signaling can alter the goblet cell balance in the gut, potentially impacting the protective mucus layer as we age.
Immune Polarisation
Aging often involves a shift toward Th2 dominance, making older individuals more prone to IL13-mediated inflammatory conditions.
Metabolic Links
Emerging research suggests IL13 may influence adipose tissue "browning" and metabolic flexibility, a process that typically declines with age.
SASP Interaction
IL13 can interact with the Senescence-Associated Secretory Phenotype (SASP) to exacerbate local tissue damage in barrier organs.
Disorders & Diseases
Allergic Asthma
The central disease of IL13. It drives the goblet cell hyperplasia, mucus hyper-secretion, and airway narrowing that define the condition.
Atopic Dermatitis
IL13 is a primary driver of the skin barrier defect and intense itching (pruritus) characteristic of eczema.
Eosinophilic Esophagitis (EoE)
A chronic allergic condition of the esophagus where IL13-driven remodeling causes swallowing difficulties.
Chronic Rhinosinusitis
IL13 promotes the formation of nasal polyps and the chronic mucosal inflammation seen in severe sinus disease.
The Decoy Receptor Link
Mutations or low levels of the IL-13Rα2 "decoy" receptor leave the body unprotected from excessive IL13 signaling, worsening all Type 2 diseases.
Interventions
Supplements
Flavonoid studied for its ability to stabilize mast cells and potentially modulate the Th2 cytokine response.
Traditional herbal remedy reported to reduce inflammatory mediators in allergic rhinitis models.
Crucial for maintaining immune balance; deficiency is strongly linked to worse outcomes in IL13-driven asthma.
Help shift the inflammatory environment away from the pro-allergic Th2 state.
Lifestyle
Reducing the allergen "load" (dust, pollen) prevents the initial dendritic cell activation that produces IL13.
Patterns like the Mediterranean diet may help lower the systemic inflammatory "tone" that favors Th2 dominance.
Helps maintain pulmonary reserve and may modulate the immune system's cytokine output over time.
Chronic stress can exacerbate the Th2 response, potentially increasing the frequency of IL13-mediated flares.
Medicines
Monoclonal antibody that blocks IL-4Rα, the shared signaling subunit for both IL-4 and IL-13.
Targeted biologics that bind and neutralize the IL13 cytokine directly.
Broadly suppress the transcription of pro-inflammatory cytokines, including IL13, in the airways.
Blocks TSLP, the "upstream" trigger that tells immune cells to start producing IL13.
Lab Tests & Biomarkers
Type 2 Markers
A direct measure of IL13 activity in the airways; IL13 induces the enzyme (iNOS) that produces NO.
Often track with IL13 levels; used to identify "Type 2 high" patients who will respond to biologics.
Genetic Testing
Testing for the Arg130Gln variant to assess baseline genetic risk for asthma and eczema.
Comprehensive sequencing of the IL-4/IL-5/IL-13 locus in complex allergic cases.
Serology
Reflects the cumulative effect of IL13 signaling on B-cell class switching.
A serum marker induced by IL13 in the lungs; once used to track treatment response in clinical trials.
Hormonal Interactions
Estrogen Activator
Generally promotes a Th2 environment; explains why asthma prevalence increases in women after puberty.
Progesterone Modulator
Can influence airway tone and inflammatory flares, particularly during the menstrual cycle.
Cortisol Inhibitor
The body's primary natural brake on IL13 production and the broader allergic response.
Thyroid Hormone Regulator
Influences the metabolic rate of immune cells and the responsiveness of the airway epithelium.
Deep Dive
Network Diagrams
The Type 2 Allergic Axis
The Effector Cytokine: Why IL13 Defines Asthma
While IL-4 is the “instruction” cytokine that tells the immune system to become allergic, IL13 is the “action” cytokine that actually carries out the damage in the airways.
Mucus Hyper-secretion: IL13 acts directly on the epithelial cells lining the lungs. It transforms them into goblet cells, which are specialized “mucus factories.” This leads to the thick, tenacious plugs that block airflow in severe asthma attacks.
Hyper-contractility: IL13 also targets the smooth muscle surrounding the airways. It makes these muscles physically larger (hypertrophy) and more sensitive to triggers like cold air or smoke. This is the biological basis for “airway hyper-reactivity.”
Remodeling: Beyond acute attacks, persistent IL13 signaling tells fibroblasts to start building scar tissue. This “airway remodeling” leads to a permanent thickening of the lung architecture, making the asthma much harder to treat as the patient ages.
The R130Q Variant: A Glue-like Mutation
The most important genetic variant in IL13 is rs20541 (Arg130Gln). This single change in the protein’s structure has profound clinical consequences.
Enhanced Stability: The mutation prevents the IL13 protein from being quickly cleared by the body’s disposal systems. As a result, carriers of the Q allele have higher and more durable levels of IL13 in their tissues.
Better Binding: The Q variant also has a higher affinity for the signaling receptor. It “sticks” to the receptor more tightly, causing a stronger and more prolonged signal for every molecule released. This explains why carriers are significantly more likely to develop asthma, hay fever, and eczema.
The Receptor Switch: Alpha-1 vs. Alpha-2
IL13 signaling is a balancing act between two distinct receptors that look similar but have opposite functions.
IL-13Rα1 (The Gas Pedal): This is the signaling receptor. When IL13 binds to it, the receptor recruits the IL-4Rα subunit, forming a complex that activates the STAT6 pathway. This is the “on” switch for all the allergic effects of IL13.
IL-13Rα2 (The Brake): This is a “decoy” receptor. It binds to IL13 with incredibly high affinity—even more than the signaling receptor—but it has no signaling tail. It acts as a molecular sponge, soaking up excess IL13 before it can cause damage.
Modern therapies often attempt to mimic the function of the decoy receptor or block the shared IL-4Rα “gas pedal,” providing a high-precision way to shut down allergic inflammation without impacting other parts of the immune system.
Practical Note: The "Type 2" Signature
FeNO is an IL13 meter. If a patient has a high FeNO score (nitric oxide in the breath), it is a direct signal that IL13 is active in the airways. These patients are the ones most likely to respond to steroids and "Type 2" biologics.
The decoys matter. Genetic variants that lower the level of the IL-13Rα2 "decoy" receptor can lead to "ultra-responsive" airways, where even small amounts of allergen cause severe, long-lasting flares.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The seminal study proving that IL13 is necessary and sufficient to induce the major features of asthma in animal models.
Identified the R130Q variant and established its significance in the genetics of human allergy.
Pivotal trial demonstrating that blocking the IL-4/IL-13 receptor provides dramatic relief in chronic allergic skin disease.
Elucidated the role of IL-13Rα2 as a natural inhibitor that prevents excessive cytokine damage.
Detailed the molecular mechanisms by which IL13 makes airway muscles physically more powerful and twitchy.